ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Hospital-Acquired Pneumonia (HAP) Drugs Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-10W7199
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Hospital acquired Pneumonia HAP Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Global Hospital-Acquired Pneumonia (HAP) Drugs Market Research Report 2025

Code: QYRE-Auto-10W7199
Report
September 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Merck
Mylan NV
Novartis
Teva Pharmaceutical Industries
Astrazeneca plc
Shinogi
Sun Pharmaceutical Industries
The Medicines Company
Theravance Biopharma

Hospital-Acquired Pneumonia (HAP) Drugs Market Size

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years.

Hospital-Acquired Pneumonia (HAP) Drugs Market

Hospital-Acquired Pneumonia (HAP) Drugs Market

The global market for Hospital-Acquired Pneumonia (HAP) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.
The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Hospital-Acquired Pneumonia (HAP) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-Acquired Pneumonia (HAP) Drugs.
The Hospital-Acquired Pneumonia (HAP) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hospital-Acquired Pneumonia (HAP) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hospital-Acquired Pneumonia (HAP) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Hospital-Acquired Pneumonia (HAP) Drugs Market Report

Report Metric Details
Report Name Hospital-Acquired Pneumonia (HAP) Drugs Market
Accounted market size in year US$ 603 billion
CAGR 5%
Base Year year
Segment by Type
  • Antibacterial
  • Antiviral
  • Antifungal
Segment by Application
  • Hospitals
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Merck, Mylan, Novartis, Teva Pharmaceutical Industries, AstraZeneca, Shinogi, Sun Pharmaceutical Industries, The Medicines Company, Theravance Biopharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Hospital-Acquired Pneumonia (HAP) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Hospital-Acquired Pneumonia (HAP) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Hospital-Acquired Pneumonia (HAP) Drugs Market report?

Ans: The main players in the Hospital-Acquired Pneumonia (HAP) Drugs Market are Pfizer, Merck, Mylan, Novartis, Teva Pharmaceutical Industries, AstraZeneca, Shinogi, Sun Pharmaceutical Industries, The Medicines Company, Theravance Biopharma

What are the Application segmentation covered in the Hospital-Acquired Pneumonia (HAP) Drugs Market report?

Ans: The Applications covered in the Hospital-Acquired Pneumonia (HAP) Drugs Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Hospital-Acquired Pneumonia (HAP) Drugs Market report?

Ans: The Types covered in the Hospital-Acquired Pneumonia (HAP) Drugs Market report are Antibacterial, Antiviral, Antifungal

1 Hospital-Acquired Pneumonia (HAP) Drugs Market Overview
1.1 Product Definition
1.2 Hospital-Acquired Pneumonia (HAP) Drugs by Type
1.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Antibacterial
1.2.3 Antiviral
1.2.4 Antifungal
1.3 Hospital-Acquired Pneumonia (HAP) Drugs by Application
1.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size Estimates and Forecasts
1.4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue 2020-2031
1.4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales 2020-2031
1.4.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Hospital-Acquired Pneumonia (HAP) Drugs Market Competition by Manufacturers
2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Hospital-Acquired Pneumonia (HAP) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Product Type & Application
2.7 Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Date of Enter into This Industry
2.8 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Competitive Situation and Trends
2.8.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Hospital-Acquired Pneumonia (HAP) Drugs Players Market Share by Revenue
2.8.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Scenario by Region
3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2020-2031
3.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2020-2025
3.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region: 2026-2031
3.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region: 2020-2031
3.3.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region: 2020-2025
3.3.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region: 2026-2031
3.4 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
3.4.1 North America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2020-2031)
3.4.3 North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
3.5.1 Europe Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2020-2031)
3.5.3 Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
3.7.1 Latin America Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2020-2031)
3.7.3 Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2020-2031)
4.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2020-2025)
4.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Type (2026-2031)
4.1.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2020-2031)
4.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2020-2031)
4.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2020-2025)
4.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Type (2026-2031)
4.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2020-2031)
5.1.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2020-2025)
5.1.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Application (2026-2031)
5.1.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2020-2031)
5.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2020-2031)
5.2.1 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2020-2025)
5.2.2 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Application (2026-2031)
5.2.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Hospital-Acquired Pneumonia (HAP) Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Mylan
6.3.1 Mylan Company Information
6.3.2 Mylan Description and Business Overview
6.3.3 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.3.5 Mylan Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Teva Pharmaceutical Industries
6.5.1 Teva Pharmaceutical Industries Company Information
6.5.2 Teva Pharmaceutical Industries Description and Business Overview
6.5.3 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.5.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Shinogi
6.7.1 Shinogi Company Information
6.7.2 Shinogi Description and Business Overview
6.7.3 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.7.5 Shinogi Recent Developments/Updates
6.8 Sun Pharmaceutical Industries
6.8.1 Sun Pharmaceutical Industries Company Information
6.8.2 Sun Pharmaceutical Industries Description and Business Overview
6.8.3 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.8.5 Sun Pharmaceutical Industries Recent Developments/Updates
6.9 The Medicines Company
6.9.1 The Medicines Company Company Information
6.9.2 The Medicines Company Description and Business Overview
6.9.3 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.9.5 The Medicines Company Recent Developments/Updates
6.10 Theravance Biopharma
6.10.1 Theravance Biopharma Company Information
6.10.2 Theravance Biopharma Description and Business Overview
6.10.3 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product Portfolio
6.10.5 Theravance Biopharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Hospital-Acquired Pneumonia (HAP) Drugs Industry Chain Analysis
7.2 Hospital-Acquired Pneumonia (HAP) Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Hospital-Acquired Pneumonia (HAP) Drugs Production Mode & Process Analysis
7.4 Hospital-Acquired Pneumonia (HAP) Drugs Sales and Marketing
7.4.1 Hospital-Acquired Pneumonia (HAP) Drugs Sales Channels
7.4.2 Hospital-Acquired Pneumonia (HAP) Drugs Distributors
7.5 Hospital-Acquired Pneumonia (HAP) Drugs Customer Analysis
8 Hospital-Acquired Pneumonia (HAP) Drugs Market Dynamics
8.1 Hospital-Acquired Pneumonia (HAP) Drugs Industry Trends
8.2 Hospital-Acquired Pneumonia (HAP) Drugs Market Drivers
8.3 Hospital-Acquired Pneumonia (HAP) Drugs Market Challenges
8.4 Hospital-Acquired Pneumonia (HAP) Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Merck
Mylan NV
Novartis
Teva Pharmaceutical Industries
Astrazeneca plc
Shinogi
Sun Pharmaceutical Industries
The Medicines Company
Theravance Biopharma
List of Tables
 Table 1. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Hospital-Acquired Pneumonia (HAP) Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Hospital-Acquired Pneumonia (HAP) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Hospital-Acquired Pneumonia (HAP) Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Hospital-Acquired Pneumonia (HAP) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital-Acquired Pneumonia (HAP) Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Hospital-Acquired Pneumonia (HAP) Drugs Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Hospital-Acquired Pneumonia (HAP) Drugs Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Hospital-Acquired Pneumonia (HAP) Drugs Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Hospital-Acquired Pneumonia (HAP) Drugs Price (USD/Unit) by Application (2026-2031)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Pfizer Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Merck Company Information
 Table 76. Merck Description and Business Overview
 Table 77. Merck Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Merck Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 79. Merck Recent Developments/Updates
 Table 80. Mylan Company Information
 Table 81. Mylan Description and Business Overview
 Table 82. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Mylan Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 84. Mylan Recent Developments/Updates
 Table 85. Novartis Company Information
 Table 86. Novartis Description and Business Overview
 Table 87. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Novartis Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 89. Novartis Recent Developments/Updates
 Table 90. Teva Pharmaceutical Industries Company Information
 Table 91. Teva Pharmaceutical Industries Description and Business Overview
 Table 92. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Teva Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 94. Teva Pharmaceutical Industries Recent Developments/Updates
 Table 95. AstraZeneca Company Information
 Table 96. AstraZeneca Description and Business Overview
 Table 97. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. AstraZeneca Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 99. AstraZeneca Recent Developments/Updates
 Table 100. Shinogi Company Information
 Table 101. Shinogi Description and Business Overview
 Table 102. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Shinogi Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 104. Shinogi Recent Developments/Updates
 Table 105. Sun Pharmaceutical Industries Company Information
 Table 106. Sun Pharmaceutical Industries Description and Business Overview
 Table 107. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Sun Pharmaceutical Industries Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 109. Sun Pharmaceutical Industries Recent Developments/Updates
 Table 110. The Medicines Company Company Information
 Table 111. The Medicines Company Description and Business Overview
 Table 112. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. The Medicines Company Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 114. The Medicines Company Recent Developments/Updates
 Table 115. Theravance Biopharma Company Information
 Table 116. Theravance Biopharma Description and Business Overview
 Table 117. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. Theravance Biopharma Hospital-Acquired Pneumonia (HAP) Drugs Product
 Table 119. Theravance Biopharma Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Hospital-Acquired Pneumonia (HAP) Drugs Distributors List
 Table 123. Hospital-Acquired Pneumonia (HAP) Drugs Customers List
 Table 124. Hospital-Acquired Pneumonia (HAP) Drugs Market Trends
 Table 125. Hospital-Acquired Pneumonia (HAP) Drugs Market Drivers
 Table 126. Hospital-Acquired Pneumonia (HAP) Drugs Market Challenges
 Table 127. Hospital-Acquired Pneumonia (HAP) Drugs Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Hospital-Acquired Pneumonia (HAP) Drugs
 Figure 2. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Type: 2024 & 2031
 Figure 4. Antibacterial Product Picture
 Figure 5. Antiviral Product Picture
 Figure 6. Antifungal Product Picture
 Figure 7. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Application: 2024 & 2031
 Figure 9. Hospitals
 Figure 10. Clinics
 Figure 11. Others
 Figure 12. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Hospital-Acquired Pneumonia (HAP) Drugs Sales (2020-2031) & (K Units)
 Figure 15. Global Hospital-Acquired Pneumonia (HAP) Drugs Average Price (USD/Unit) & (2020-2031)
 Figure 16. Hospital-Acquired Pneumonia (HAP) Drugs Report Years Considered
 Figure 17. Hospital-Acquired Pneumonia (HAP) Drugs Sales Share by Manufacturers in 2024
 Figure 18. Global Hospital-Acquired Pneumonia (HAP) Drugs Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Hospital-Acquired Pneumonia (HAP) Drugs Players: Market Share by Revenue in Hospital-Acquired Pneumonia (HAP) Drugs in 2024
 Figure 20. Hospital-Acquired Pneumonia (HAP) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Hospital-Acquired Pneumonia (HAP) Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2020-2031)
 Figure 23. North America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2020-2031)
 Figure 27. Europe Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Region (2020-2031)
 Figure 35. China Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Hospital-Acquired Pneumonia (HAP) Drugs Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. U.A.E Hospital-Acquired Pneumonia (HAP) Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Hospital-Acquired Pneumonia (HAP) Drugs by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Hospital-Acquired Pneumonia (HAP) Drugs by Type (2020-2031)
 Figure 57. Global Hospital-Acquired Pneumonia (HAP) Drugs Price (USD/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Hospital-Acquired Pneumonia (HAP) Drugs by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Hospital-Acquired Pneumonia (HAP) Drugs by Application (2020-2031)
 Figure 60. Global Hospital-Acquired Pneumonia (HAP) Drugs Price (USD/Unit) by Application (2020-2031)
 Figure 61. Hospital-Acquired Pneumonia (HAP) Drugs Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6Q20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35Z19949
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26E19785
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions